Background: The availability of a commercial test for the breast cancer susceptibility genes, BRCA1 and BRCA2, has generated interest in both the medical community and the general public.
Methods: Patients and family members were approached in the waiting room and asked to fill out an anonymous questionnaire about their awareness of breast cancer genes and breast cancer gene testing, and their desire to be tested. chi2 analysis was used to analyze frequencies between groups.
Results: A total of 354 women completed a questionnaire concerning the breast cancer genes BRCA1 and BRCA2. The very young, the very old, and African-Americans were the least informed in terms of awareness of the genes and the availability of testing for the breast cancer susceptibility genes. Jewish people, people with a college education or beyond, people earning more than $30,000 a year, and Caucasians were more aware of the genes and of testing for these genes. Interest in being tested was similar in all groups, except for participants over 60 and those who had only an elementary-school education.
Conclusions: Information concerning the breast cancer susceptibility genes has not reached the general public uniformly. A concerted effort is needed if this information is to be passed on to those people at risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02303830 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Musculoskeletal problems, or aromatase inhibitor-associated musculoskeletal syndrome, in the hands and wrists is a known side effect of aromatase inhibitor medication, often prescribed for 5years or more for breast cancer survivors. No studies were found on the effectiveness of hand therapy for breast cancer survivors experiencing aromatase inhibitor-associated musculoskeletal syndrome in the hands and wrists.
Purpose: The primary objective of this study is to determine the effectiveness of hand therapy on reducing hand and wrist pain, improving grip strength, improving upper extremity function, and improving health related quality of life in breast cancer survivors diagnosed with aromatase inhibitor-associated musculoskeletal syndrome in the hands and wrists.
Corrigendum to "Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer - efficacy, tolerability and quality of life results from the phase II METRO trial" [The Breast 78 (2004) 103795].
Breast
March 2025
Department of Oncology, Sahlgrenska University Hospital, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden.
Corrigendum to "Antibody-Drug conjugates in elderly patients with breast cancer" [The Breast 80 (2025) 104428].
Breast
March 2025
Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
Best practice offloading treatments for diabetic foot ulcer healing, remission, and better plans for the healing-remission transition.
Semin Vasc Surg
March 2025
Australian Centre for Health Services Innovation & Centre for Healthcare Transformation, School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia; Department of Rehabilitation Medicine, Amsterdam Movement Sciences,Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Diabetes-related foot disease is arguably the world's least known major health problem and causes a disease burden larger than most well-known diseases, such as stroke and breast cancer. This burden is driven by people developing more severe stages of foot disease, such as foot ulcers and infections, and with that worsening quality of life. To reduce this burden, we need treatments that prevent more severe stages of foot disease and improve quality of life.
View Article and Find Full Text PDFIdentification of functional biomarkers for personalized nanomedicine in advanced breast cancer in vitro models.
J Control Release
March 2025
Polymer Therapeutics Lab, Centro de Investigación Príncipe Felipe, Av. Eduardo Primo Yúfera 3, Valencia 46012, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCCIII, Madrid, Spain. Electronic address:
Nanomedicines represent promising advanced therapeutics for the enhanced treatment of breast cancer, the primary cause of cancer-related deaths in women; however, the clinical translation of nanomedicines remains challenging. Advanced in vitro models of breast cancer may improve preclinical evaluations and the identification of biomarkers that aid the stratification of patients who would benefit from a given nanomedicine. In this study, we first developed a matrix-embedded breast cancer cell spheroid model representing the extracellular matrix and confirmed the faithful recapitulation of disease aggressiveness in vitro.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!